Any current/future new fundraising through debt or equity?

There is no mention of any current or future fundraising through debt or equity in the provided transcript. The management did not indicate plans for raising capital via equity or debt during this period. CAPEX plans totaling Rs.100 crore over 15 months are funded internally for facility upgrades rather than through external fundraising. The focus appears to be on organic growth through clinical trial progress and CRAMS business expansion. No guidance or discussion was provided regarding capital raising activities in the call.

Any current/future capex/capital investment/strategic investment?

Suven Life Sciences plans a significant capital expenditure (CAPEX) of Rs.100 crore over a 15-month period starting FY17. This investment is for the construction of an additional block and upgradation of facilities at the CRAMS business site in Pashamylaram. The CAPEX includes both recurring/replacement CAPEX of Rs.15 crore to Rs.20 crore annually and the new CAPEX for expansion. Initial FY17 CAPEX is expected to be around Rs.20 crore as part of regular CAPEX. For FY18, the company initially considered Rs.50 crore for facility upgradation but expanded it to Rs.100 crore by adding a new block.

Future growth expectations in sales/revenue/volumes?

Core CRAMS business expected to grow by 10% to 15% annually, as mentioned by Venkat Jasti. Specialty chemicals segment is mature with flat or marginal growth expected (±5%). Repeat business orders estimated around Rs. 40-50 crore in the next fiscal years (FY18-FY19). No significant top-line growth currently; future growth depends on molecules in the pipeline advancing to next stages. Clinical trial progress, especially on SUVN-502, is crucial for unlocking potential out-licensing deals and revenue growth. New CAPEX of Rs. 100 crore planned for CRAMS facility enhancement to support fu

Future growth expectations in earnings/operating earnings/profits/EPS?

Suven Life Sciences expects core CRAMS business growth of about 10% to 15% annually, reflecting mature yet steady expansion. EBITDA margins are anticipated to remain strong around 30% for the next one to two quarters, driven by better product mix and difficult-to-make projects commanding higher prices. Specialty chemicals segment is expected to be flat or fluctuate within a ±5% range, indicating limited growth potential. Commercial repeat orders estimated between Rs. 40 crore to Rs. 50 crore for the next two years, providing steady revenue support. Pipeline advancement: Positive results from N

Current/ Expected Orderbook/ Pending Orders?

As of the call, there are no pending orders for the three commercialized molecules. The company expects repeat business/orders in the range of Rs. 40 crore to Rs. 50 crore for the next two years. For the specialty chemicals segment, the revenue is expected to remain flat with possible variation of +/- 5%. In the CRAMS business, the company anticipates growth of around 10% to 15%. Rs. 30 crore worth of molecule repeat orders were expected in the current quarter; Rs. 15 crore executed so far. Anticipated orders of Rs. 70 crore to Rs. 80 crore expected in the fourth quarter, partly seasonal. No n

Suven Life Sciences LtdQ3 FY17Healthcare Services

Suven Life Sciences Ltd Q3 FY17 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹308Market Cap: ₹9.5K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

Core CRAMS business expected to grow by 10% to 15% annually, as mentioned by Venkat Jasti.
Specialty chemicals segment is mature with flat or marginal growth expected (±5%).
Repeat business orders estimated around Rs. 40-50 crore in the next fiscal years (FY18-FY19).
No significant top-line growth currently; future growth depends on molecules in the pipeline advancing to next stages.
Clinical trial progress, especially on SUVN-502, is crucial for unlocking potential out-licensing deals and revenue growth.
New CAPEX of Rs. 100 crore planned for CRAMS facility enhancement to support future business opportunities.
Expected EBITDA margins sustained at around 30%, supporting profitability growth.
Specialty chemical revenues likely to remain around Rs. 200 crore range, with minor year-on-year variances.

Margin guidance

Category 3

Suven Life Sciences expects core CRAMS business growth of about 10% to 15% annually, reflecting mature yet steady expansion.
EBITDA margins are anticipated to remain strong around 30% for the next one to two quarters, driven by better product mix and difficult-to-make projects commanding higher prices.
Specialty chemicals segment is expected to be flat or fluctuate within a ±5% range, indicating limited growth potential.
Commercial repeat orders estimated between Rs. 40 crore to Rs. 50 crore for the next two years, providing steady revenue support.
Pipeline advancement: Positive results from NCE Phase-2 trials (e.g., SUVN-502) could catalyze top-line and bottom-line growth, but no definitive timeline or guarantees yet.
Overall, profits and EPS growth hinge on successful clinical trial outcomes and pipeline progress; management is optimistic but cautious.

See what Suven Life Sciences Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or future fundraising through debt or equity in the provided transcript.
The management did not indicate plans for raising capital via equity or debt during this period.
CAPEX plans totaling Rs.100 crore over 15 months are funded internally for facility upgrades rather than through external fundraising.
The focus appears to be on organic growth through clinical trial progress and CRAMS business expansion.
No guidance or discussion was provided regarding capital raising activities in the call.

Order book

As of the call, there are no pending orders for the three commercialized molecules.
The company expects repeat business/orders in the range of Rs. 40 crore to Rs. 50 crore for the next two years.
For the specialty chemicals segment, the revenue is expected to remain flat with possible variation of +/- 5%.
In the CRAMS business, the company anticipates growth of around 10% to 15%.
Rs. 30 crore worth of molecule repeat orders were expected in the current quarter; Rs. 15 crore executed so far.
Anticipated orders of Rs. 70 crore to Rs. 80 crore expected in the fourth quarter, partly seasonal.
No new significant out-licensing deals or orders are currently confirmed.
The company is focusing more on the CRAMS business for top-line and margin growth.

See what Suven Life Sciences Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Suven Life Sciences plans a significant capital expenditure (CAPEX) of Rs.100 crore over a 15-month period starting FY17.
This investment is for the construction of an additional block and upgradation of facilities at the CRAMS business site in Pashamylaram.
The CAPEX includes both recurring/replacement CAPEX of Rs.15 crore to Rs.20 crore annually and the new CAPEX for expansion.
Initial FY17 CAPEX is expected to be around Rs.20 crore as part of regular CAPEX.
For FY18, the company initially considered Rs.50 crore for facility upgradation but expanded it to Rs.100 crore by adding a new block.
This investment aims to enhance containment facilities and handle new chemical entities, supporting future growth in CRAMS.
No other specific strategic investments or out-licensing deals currently announced; focus remains on facility upgrades and clinical trial progression.

Track Suven Life Sciences Ltd — get its next earnings analysis in your feed

How does Suven Life Sciences Ltd rank vs peers in Healthcare Services?

Pro feature

ThisSuven Life Sciences Ltd

Rev 4Mar 3

See where Suven Life Sciences Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Suven Life Sciences Ltd rank in Healthcare Services?

Compare Suven Life Sciences Ltd against every Healthcare Services company (Q3 FY17) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Suven Life Sciences Ltd's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
3B Blackbio DX Ltd (Q4 FY24)
41% increase). Key concall takeaways from 3B Blackbio DX Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →